Published in Hepatitis Weekly, September 23rd, 2002
Both therapeutic regimens are standard for individuals infected with HCV. However, after studying a cohort of 26 patients with HCV genotype 4-related cirrhosis who were given either of the regimens, investigators from the St. Johns Medical College Hospital in Karnataka, India, argue that neither regimen is very effective for such individuals.
The 26 patients were randomized to take interferon alone or interferon in combination...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.